ABT · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

ABBOTT LABORATORIES · 2026-11-04 · Importance 64 · Surprise 56 · From source text

Third-quarter 2026 net sales rose 14.5% year over year to $13.013 billion, or 14.8% excluding foreign exchange; nine-month sales rose 11.9% to $36.770 billion, or 10.5% excluding foreign exchange. In the first nine months, Medical Devices sales increased 9.6% to $17.218 billion, Established Pharmaceutical Products increased 9.3% to $4.539 billion, Diagnostic Products increased 32.4% to $8.577 billion, and Nutritional Products declined 1.3% to $6.423 billion. Diagnostic Products growth included approximately $2.0 billion of acquired Exact Sciences sales reported as Cancer Diagnostics; excluding foreign exchange, Nutrition declined 2.1%, reflecting lower adult and U.S. pediatric volumes. U.S. sales increased 17.7% to $14.994 billion in the first nine months, while international sales increased 8.2% to $21.776 billion, including a 2.3% favorable foreign-exchange impact.

Key facts

• CGM systems sales totaled $6.2 billion in the first nine months of 2026 and $5.6 billion in the first nine months of 2025, increasing 8.3% excluding foreign exchange. source
• Diagnostic Products sales increased 30.8% excluding foreign exchange in the first nine months of 2026; Exact Sciences inclusion and Core Laboratory growth were partly offset by a Rapid and Molecular Diagnostics decline. source
• Nutritional Products sales decreased 2.1% excluding foreign exchange in the first nine months of 2026, reflecting lower volumes across adult nutrition and U.S. pediatric products. source
• Core Laboratory sales increased 4.0% excluding foreign exchange in the first nine months of 2026, reflecting Alinity platform test growth in the U.S. and international markets, partly offset by lower China sales amid challenging conditions. source
• Rapid and Molecular Diagnostics sales decreased 5.4% excluding foreign exchange in the first nine months of 2026, primarily reflecting lower demand for respiratory virus tests. source
• Medical Devices sales increased 7.8% excluding foreign exchange in the first nine months of 2026, reflecting double-digit Electrophysiology and Rhythm Management growth and high-single-digit Heart Failure and Diabetes Care growth. source
• Diabetes Care sales increased 7.7% excluding foreign exchange in the first nine months of 2026, driven by growth in Abbott’s CGM systems in the U.S. and internationally. source
• Heart Failure sales increased 8.9% excluding foreign exchange in the first nine months of 2026, primarily reflecting growth in ventricular assist devices and related accessories. source

Impact estimates